Neurosense Therapeutics Ltd Financial Flexibility Index
Neurosense Therapeutics Ltd financial flexibility index. Neurosense Therapeutics Ltd (NRSN) has a Financial Flexibility Index of -0.71x as of December 2025. Free cash flow of $-1.83 Million (operating CF $-1.84 Million minus capex $1.50K) represents -1% of total liabilities ($2.59 Million). See Neurosense Therapeutics Ltd (NRSN) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Neurosense Therapeutics Ltd (2019–2025)
Financial flexibility index of Neurosense Therapeutics Ltd from 2019 to 2025. Historical Financial Flexibility Index trend for Neurosense Therapeutics Ltd across 7 annual periods. Explore Neurosense Therapeutics Ltd (NRSN) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Neurosense Therapeutics Ltd Financial Flexibility Index by Year (2019–2025)
Neurosense Therapeutics Ltd financial flexibility index by year from 2019 to 2025. Year-by-year free cash flow to debt coverage for Neurosense Therapeutics Ltd. For the full cash flow conversion analysis, see NRSN cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.96x | $-7.66 Million | $-7.67 Million | $2.59 Million | ▲ +41.8% |
| 2024 | -5.09x | $-10.13 Million | $-10.13 Million | $1.99 Million | ▼ -202.1% |
| 2023 | -1.68x | $-8.32 Million | $-8.35 Million | $4.94 Million | ▲ +53.2% |
| 2022 | -3.59x | $-7.52 Million | $-7.59 Million | $2.09 Million | ▼ -472.7% |
| 2021 | -0.63x | $-1.52 Million | $-1.54 Million | $2.42 Million | ▲ +89.0% |
| 2020 | -5.72x | $-686.00K | $-695.00K | $120.00K | ▲ +63.2% |
| 2019 | -15.54x | $-575.00K | $-582.00K | $37.00K | — |